A major clinical trial reveals Wegovy a popular weight loss drug also treats serious liver disease MASH—reducing liver inflammation and scarring in most patients ...

Amgen Inc. outperformed Wall Street’s quarterly profit estimates as it moves forward with plans to crack the ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.

The IMPACT trial reinforces the need to check for antiphospholipid syndrome in women after they experience stillbirth and is ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...